TrialNature medicine2020

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.

Reinhard Dummer et al.PubMed ↗Publisher ↗

No numbers read from the abstract.